Sterling Pharma Solutions, a global CDMO, has appointed Stewart Mitchell as site head of its new antibody-drug conjugate (ADC) facility in Deeside, UK. Dr. Mitchell will lead the Deeside facility, and report to Kevin Cook, Sterling’s Chief Executive Officer. He succeeds Alan Raymond, who has been acting general manager since Sterling acquired ADC Bio.   Dr. Mitchell brings more than 25 years of industry experience having previously managed sites in the UK and U.S. for companies including ...